Previous Close | 1,660.80 |
Open | 1,662.00 |
Bid | 1,665.80 x 0 |
Ask | 1,666.00 x 0 |
Day's Range | 1,655.60 - 1,666.20 |
52 Week Range | 1,302.60 - 1,725.81 |
Volume | |
Avg. Volume | 8,990,086 |
Market Cap | 67.623B |
Beta (5Y Monthly) | 0.26 |
PE Ratio (TTM) | 13.88 |
EPS (TTM) | 1.20 |
Earnings Date | May 01, 2024 |
Forward Dividend & Yield | 0.64 (3.85%) |
Ex-Dividend Date | Feb 22, 2024 |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for GSK.L
Pfizer is raising around $4.27 billion from the sale of part of its stake in consumer-healthcare business Haleon.
(Bloomberg) -- Pfizer Inc. has sold over £3 billion ($3.8 billion) of shares in Haleon Plc, the first step by the UK consumer health company’s biggest shareholder to reduce its 32% stake. Most Read from BloombergApple Is in Talks to Let Google Gemini Power iPhone AI FeaturesTrump Rules Out Vivek Ramaswamy as Running Mate as He Eyes New TeamNvidia Unveils Successor to Its All-Conquering AI ProcessorMusk Says His Ketamine Prescription Is in Investors’ Best InterestsEvergrande’s Alleged $78 Billion
AstraZeneca’s move on Monday to cap at $35 the out-of-pocket costs that patients pay for the company’s Symbicort inhaler speaks to the political and regulatory pressure coming to bear on manufacturers of certain commonly used but expensive treatments. The British drugmaker’s shift follows a similar step last month by Boehringer Ingelheim, which sells rival inhalers including Atrovent and Spiriva. Sen. Bernie Sanders, the independent from Vermont, launched an investigation of inhaler prices in January.